Abstract:Background: Emerging evidence suggests that Eph/ephrin-system involves different facets of tumorigenesis and cancer progression. Whether ephrin-A3, a cognate ligand to several Eph receptors, plays a role in HCC cell proliferation and metastasis remains unclear. Methods: The expression of ephrin-A3 was detected by immunohistochemistry and qRT-PCR in human HCC tissues. The clinical significance of ephrin-A3 was analyzed using multiple databases. The biological functions of ephrin-A3 were investigated in vitro and in vivo. Immunofluorescence and co-immunoprecipitation were used to detect the interaction between ephrin-A3 and EphA2. Findings: Elevated expression of ephrin-A3 was positively correlated with the histological grade, metastasis and poor prognosis in human HCC. Knockdown of ephrin-A3 led to significantly decreased proliferative activity and metastatic potential, and re-introduction of ephrin-A3 rescued the decreased proliferation, migration, and invasion induced by ephrin-A3 knockdown in HCC cells. Ephrin-A3 interacted with EphA2 and positively regulated EphA2 and AKT phosphorylation. Knockdown of EphA2 attenuated HCC cell proliferation, migration, and invasion induced by ephrin-A3 overexpression. Furthermore, ephrin-A3-induced EphA2 phosphorylation is both a substrate and a positive regulator of AKT. In HCC tissues, ephrin-A3 expression was positively correlated with EphA2, and patients with high co-expression of ephrin-A3 and EphA2 exhibited poorer prognosis. Interpretation: Ephrin-A3 promotes HCC metastasis by interacting with EphA2 and activating EphA2 and AKT. Thus, our study implicates ephrin-A3 and EphA2 as potential prognostic biomarkers, and provides valuable information for HCC prognosis and treatment. Funding Statement: This work was supported in part by grants from the National Natural Science Foundation of China (81672832), Outstanding Subject Leader Training Program of Shanghai Municipal Commission of Health and Family Planning (2018BR20), the National Natural Science Foundation of Shanghai (20ZR1454000), the National Key Sci-Tech Special Project of China (2018ZX10723204-006), the Research Project of Shanghai Municipal Commission of Health and Family Planning (20204Y0093), and the Grants from the State Key Laboratory of Oncogenes and Related Genes (91-17-18). Declaration of Interests: The authors declare that they have no competing interests. Ethics Approval Statement: The study was approved by the Research Ethics Committee of Renji Hospital, Shanghai Jiao Tong University School of Medicine, and informed consent was obtained from each patient from the Zhejiang University (Hangzhou, China) and the Qidong Liver Cancer Institute (Qidong, China).

Ephrin Type-B Receptor 4 Affinity Chromatography: an Effective and Rapid Method Studying the Active Compounds Targeting Ephrin Type-B Receptor 4.

Development of target-based cell membrane affinity ultrafiltration technology for a simplified approach to discovering potential bioactive compounds in natural products

Advance of molecular imaging probes targeted for EphB4 receptor

Design, Synthesis and Characterization of Novel Small Molecular Inhibitors of Ephrin-B2 Binding to EphB4.

A Synthetic Bivalent Peptide Ligand of EphB4 with Potent Agonistic Activity

An investigation of binding interactions of tumor-targeted peptide conjugated polyphenols with the kinase domain of ephrin B4 and B2 receptors

Biomimetic Cell-Cell Adhesion Capillary Electrophoresis for Studying Gu-4 Antagonistic Interaction Between Cell Membrane Receptor and Ligands

Application of SNAP-tag-EGFR cell membrane chromatography model in screening antitumor active components of Silybum marianum (L.) Gaertn

Ephrin-A3 Promotes Hepatocellular Carcinoma Cell Proliferation and Metastasis by Interacting with EphA2

Effective Tumor Targeting by EphA2-Agonist-Biotin-Streptavidin Conjugates

In vivo small-animal PET/CT of EphB4 receptors using64Cu-labeled peptide

Abstract B201: Selective Peptides for Targeting EphA2 in Cancer Cells

Discovery And Characterization Of A Novel Cyclic Peptide That Effectively Inhibits Ephrin Binding To The Epha4 Receptor And Displays Anti-Angiogenesis Activity

A novel cell membrane affinity sample pretreatment technique for recognition and preconcentration of active components from traditional Chinese medicine

Uncovering the key pharmacodynamic material basis and possible molecular mechanism of extract of Epimedium against liver cancer through a comprehensive investigation

Identifying of Anti-Thrombin Active Components From Curcumae Rhizoma by Affinity-Ultrafiltration Coupled With UPLC-Q-Exactive Orbitrap/MS

Targeting Pharmacophore with Probe-Reactivity-guided Fractionation to Precisely Identify Electrophilic Sesquiterpenes and Its Activity of Anti-Tnbc

Developing an activity and absorption-based quality control platform for Chinese traditional medicine: Application to Zeng-Sheng-Ping(Antitumor B)

Exploring the Potential Pharmacologic Mechanism of Heterophyllin B in the Treatment of Esophageal Cancer by Network Pharmacology

Targeting the EphB4 receptor tyrosine kinase sensitizes HER2-positive breast cancer cells to Lapatinib

Profiling Eph receptor expression in cells and tissues